

Increased microvessel density in involved organs from patients with HTLV-I associated adult T cell leukemia lymphoma

Kchour, G.^a, Tarhini, M.^b, Sharifi, N.^b, Farid, R.^a, Khooei, A.R.^b, Shirdel, A.^c, Afshari, J.T.^a, Sadeghian, A.^b, Otrouk, Z.^d, Hermine, O.^e, El-Sabban, M.^f, Bazarbachi, A.^g

^a Immunology Research Centre, Bu-Ali Research Institute, **Mashhad University of Medical Sciences, Mashhad, Iran**

^b Department of Pathology and Laboratory Medicine, **Mashhad University of Medical Sciences, Mashhad, Iran**

^c Department of Internal Medicine, **Mashhad University of Medical Sciences, Mashhad, Iran**

^d Department of Pathology and Laboratory Medicine, **American University of Beirut, Beirut, Lebanon**

^e CNRS UMR 5102, Department of Hematology, Necker Hospital, Paris, France

^f Department of Human Morphology, **American University of Beirut, Beirut, Lebanon**

^g Department of Internal Medicine, **American University of Beirut, Beirut, Lebanon**

[View references \(10\)](#)

Abstract

Adult T-cell leukemia-lymphoma (ATLL) is a rapidly progressive lymphoproliferative disorder secondary to infection with the human T cell lymphotropic virus type I (HTLV-I). The role of angiogenesis in the development and prognosis of many hematologic malignancies is established. We have previously shown that ATLL derived cells secrete high levels of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (b-FGF), induce endothelial tube formation in vitro and establish functional gap junction-mediated communication with endothelial cells. We also demonstrated that plasma from ATLL and tropical spastic paraparesis/HTLV-I associated myelopathy patients exhibit very high levels of VEGF and b-FGF. Recently, we showed that treatment with the combination of zidovudine and interferon alpha reduced both HTLV-I proviral load and importantly VEGF plasma levels suggesting a potential anti-angiogenic effect of this therapy. In this report, we evaluated microvessel density (MVD) in involved organs from 20 patients with ATLL, as compared to normal organs from matched controls. We show evidence of significantly increased MVD in all tested involved organs from ATLL patients, suggesting that angiogenesis plays an important role in the development or organ invasion of ATLL, and could represent a potentially interesting target for anti-angiogenic therapy of ATLL.

Reaxys Database Information

Author keywords

Angiogenesis; ATLL; HTLV-I; Microvessel density; VEGF

Indexed Keywords

EMTREE drug terms: alpha interferon; angiogenesis inhibitor; basic fibroblast growth factor; vasculotropin; zidovudine

EMTREE medical terms: adult; aged; angiogenesis; antiangiogenic activity; article; bone marrow; clinical article; colon; controlled study; female; human; Human T cell leukemia virus 1; human tissue; lymph node; male; microvasculature; pathogenesis; priority journal; protein blood level; skin; spastic paraplegia; spinal cord disease; T cell leukemia; T cell lymphoma; vascular endothelium; virus infection; virus load

MeSH: Adult; Aged; Bone Marrow; Capillaries; Case-Control Studies; Female; Human T-lymphotropic virus 1; Humans; Immunohistochemistry; Leukemia-Lymphoma, Adult T-Cell; Lymph Nodes; Male; Middle Aged; Neovascularization, Pathologic; Skin; Testis

Medline is the source for the MeSH terms of this document.